Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : MD-18
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Radella Pharmaceuticals Reports Phase 1a MD-18 Results Targeting Obesity with PTP1B
Details : MD-18 is a first-in-class peptide that targets targeting protein-tyrosine phosphatase 1B (PTP1B) involved in obesity and related metabolic conditions.
Brand Name : MD-18
Molecule Type : Peptide
Upfront Cash : Not Applicable
November 07, 2024
Lead Product(s) : MD-18
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?